People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| DermBiont, Inc. | — | Biotechnology | Series B | $114.2M | $320.8M | 2023 |
Daniel R. Yadegar at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Daniel R. Yadegar on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven R. Basta | 1 | 1 |
| Karl R. Beutner | 1 | 1 |
| Nichola R. Eliovits | 1 | 1 |
| Max R. Dawson | 1 | 1 |
| Wilder R. Ramsey | 1 | 1 |
| Jennifer R. Lee | 1 | 1 |
| Ramsey R. Wilder | 1 | 1 |
| Robert R. Brucker | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.